This study is evaluating an investigational approach that uses immune cells called T cells to kill B-cell acute lymphoblastic leukemia (ALL) that has returned, stopped responding to therapy, or is in first remission and at risk of returning. The T cells are removed from the patient’s blood, modified in a laboratory, and then returned to the patient’s body.
Investigators put a gene in the patient’s T cells that allows them to recognize and kill leukemia cells. The gene will produce a protein in T cells that helps them recognize leukemia cells and possibly kill them. Researchers have found that T cells modified in this way can cure an ALL-like cancer in laboratory studies.